{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:16:18Z","timestamp":1791350178809,"version":"4.3.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AbbVie"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Atogepant is an oral calcitonin gene\u2013related peptide receptor antagonist approved for the preventive treatment of migraine in adults. These analyses evaluated the proportions of clinical trial participants who experienced sustained responses to atogepant over 12 or 52 weeks of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>These were post hoc analyses of ADVANCE, a 12-week, double-blind, randomized trial of atogepant 10, 30, and 60\u00a0mg once daily vs. placebo for the preventive treatment of episodic migraine, and a separate open-label long-term safety (LTS) trial of atogepant 60\u00a0mg once daily over 52 weeks. The 60\u00a0mg dose of atogepant was used to detect safety issues. An initial response was defined as \u226550%, \u226575%, or 100% reduction from baseline in MMDs in month 1 for ADVANCE or quarter 1 for the LTS trial. The proportions of participants who continued to experience a response above each response-defining threshold through each subsequent month (for ADVANCE) or each quarter (for LTS) were calculated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In ADVANCE, sustained response rates during months 2 and 3 varied with dose and were as follows: 70.8\u201381.1% following an initial \u226550% response, 47.3\u201361.9% following an initial \u226575% response, and 34.8\u201341.7% following an initial 100% response. Of those who experienced an initial \u226575% or 100% response during month 1, more than 79% continued to experience at least a 50% response during both months 2 and 3. During the LTS trial, sustained response rates through quarters 2, 3, and 4 were 84.7% following an initial \u226550% response, 72.6% following an initial \u226575% response, and 37.8% following an initial 100% response. Of those who experienced an initial \u226575% or 100% response during quarter 1, more than 90% continued to experience at least a 50% response through quarters 2, 3, and 4.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Over 70% of participants who experienced an initial response with atogepant treatment had a sustained response with continued treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov: NCT03777059 (submitted: December 13, 2018); NCT03700320 (submitted: September 25, 2018).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-024-01783-6","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T07:05:14Z","timestamp":1716275114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Richard B.","family":"Lipton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Nahas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Bilchik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McAllister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Finnegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natty","family":"Chalermpalanupap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Dabruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Dodick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"1783_CR1","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1-211","DOI":"10.1177\/0333102417738202"},{"key":"1783_CR2","unstructured":"(2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the global burden of Disease Study 2015. Lancet 388:1545\u20131602"},{"key":"1783_CR3","unstructured":"(2018) Global, regional, and national burden of migraine and tension-type headache, 1990\u20132016: a systematic analysis for the global burden of Disease Study 2016. Lancet Neurol 17:954\u2013976"},{"key":"1783_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21:137","journal-title":"J Headache Pain"},{"key":"1783_CR5","first-page":"1334","volume":"26","author":"DC Buse","year":"2020","unstructured":"Buse DC, Yugrakh MS, Lee LK, Bell J, Cohen JM, Lipton RB (2020) Burden of illness among people with migraine and \u22654 monthly headache days while using acute and\/or preventive prescription medications for migraine. J Manag Care Spec Pharm 26:1334\u20131343","journal-title":"J Manag Care Spec Pharm"},{"key":"1783_CR6","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Fanning KM, Reed ML, Murray S, Dumas PK, Adams AM et al (2019) Life with migraine: effects on relationships, career, and finances from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache 59:1286\u20131299","journal-title":"Headache"},{"key":"1783_CR7","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/head.13407","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Munjal S, Alam A, Buse DC, Fanning KM, Reed ML et al (2018) Migraine in America Symptoms and Treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache 58:1408\u20131426","journal-title":"Headache"},{"key":"1783_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s10194-020-1084-y","volume":"21","author":"DC Buse","year":"2020","unstructured":"Buse DC, Reed ML, Fanning KM, Bostic R, Dodick DW, Schwedt TJ et al (2020) Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the Migraine in America Symptoms and Treatment (MAST) study. J Headache Pain 21:23","journal-title":"J Headache Pain"},{"key":"1783_CR9","first-page":"19","volume":"258","author":"S Miller","year":"2014","unstructured":"Miller S, Matharu MS (2014) Migraine is underdiagnosed and undertreated. Practitioner 258:19\u201324","journal-title":"Practitioner"},{"key":"1783_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/0333102416636055","volume":"37","author":"M Torres-Ferr\u00fas","year":"2017","unstructured":"Torres-Ferr\u00fas M, Quintana M, Fernandez-Morales J, Alvarez-Sabin J, Pozo-Rosich P (2017) When does chronic migraine strike? A clinical comparison of migraine according to the headache days suffered per month. Cephalalgia 37:104\u2013113","journal-title":"Cephalalgia"},{"key":"1783_CR11","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS (2021) The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61:1021\u20131039","journal-title":"Headache"},{"key":"1783_CR12","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1177\/0333102414547138","volume":"35","author":"Z Hepp","year":"2015","unstructured":"Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35:478\u2013488","journal-title":"Cephalalgia"},{"key":"1783_CR13","first-page":"22","volume":"20","author":"Z Hepp","year":"2014","unstructured":"Hepp Z, Bloudek LM, Varon SF (2014) Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 20:22\u201333","journal-title":"J Manag Care Pharm"},{"key":"1783_CR14","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/head.12055","volume":"53","author":"AM Blumenfeld","year":"2013","unstructured":"Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA et al (2013) Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second International Burden of Migraine Study (IBMS-II). Headache 53:644\u2013655","journal-title":"Headache"},{"key":"1783_CR15","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1111\/head.13202","volume":"57","author":"JH Ford","year":"2017","unstructured":"Ford JH, Jackson J, Milligan G, Cotton S, Ahl J, Aurora SK (2017) A real-world analysis of migraine: a cross-sectional study of disease burden and treatment patterns. Headache 57:1532\u20131544","journal-title":"Headache"},{"key":"1783_CR16","unstructured":"Qulipta [package insert] (2023) AbbVie"},{"key":"1783_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L et al (2021) Atogepant for the preventive treatment of migraine. N Engl J Med 385:695\u2013706","journal-title":"N Engl J Med"},{"key":"1783_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/head.14439","volume":"63","author":"M Ashina","year":"2023","unstructured":"Ashina M, Tepper SJ, Reuter U, Blumenfeld AM, Hutchinson S, Xia J et al (2023) Once-daily oral atogepant for the long-term preventive treatment of migraine: findings from a multicenter, randomized, open-label, phase 3 trial. Headache 63:79\u201388","journal-title":"Headache"},{"key":"1783_CR19","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1474-4422(20)30234-9","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K et al (2020) Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol 19:727\u2013737","journal-title":"Lancet Neurol"},{"key":"1783_CR20","doi-asserted-by":"publisher","first-page":"333102422112825","DOI":"10.1177\/03331024221128250","volume":"43","author":"BC Klein","year":"2023","unstructured":"Klein BC, Miceli R, Severt L, McAllister P, Mechtler L, McVige J et al (2023) Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial. Cephalalgia 43:3331024221128250","journal-title":"Cephalalgia"},{"key":"1783_CR21","unstructured":"US Food and Drug Administration. Migraine: developing drugs for preventive treatment. Guidance for Industry: US Food and Drug Administration (2023) [June 2023]. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/migraine-developing-drugs-preventive-treatment"},{"issue":"suppl 1","key":"1783_CR22","first-page":"60","volume":"62","author":"DC Buse","year":"2022","unstructured":"Buse DC, Reed ML, Fanning KM, Dabruzzo BL, Lipton RB (2022) Characterizing preventive treatment gaps in migraine: interim results from the CaMEO-International study United States sample [abstract IOR-05]. Headache 62(suppl 1):60\u201361","journal-title":"Headache"},{"key":"1783_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s10194-023-01539-8","volume":"24","author":"L Al-Hassany","year":"2023","unstructured":"Al-Hassany L, Lyons HS, Boucherie DM, Farham F, Lange KS, Marschollek K et al (2023) The sense of stopping migraine prophylaxis. J Headache Pain 24:9","journal-title":"J Headache Pain"},{"key":"1783_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","volume":"23","author":"S Sacco","year":"2022","unstructured":"Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013\u20092022 update. J Headache Pain 23:67","journal-title":"J Headache Pain"},{"key":"1783_CR25","doi-asserted-by":"crossref","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A (2024) Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache 64:333\u2013341","DOI":"10.1111\/head.14692"},{"key":"1783_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0333102411417901","volume":"32","author":"P Tfelt-Hansen","year":"2012","unstructured":"Tfelt-Hansen P, Pascual J, Ramadan N, Dahlof C, D\u2019Amico D, Diener HC et al (2012) Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 32:6\u201338","journal-title":"Cephalalgia"},{"key":"1783_CR27","doi-asserted-by":"publisher","first-page":"e2215499","DOI":"10.1001\/jamanetworkopen.2022.15499","volume":"5","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, Pozo-Rosich P, Blumenfeld AM, Dodick DW, McAllister P, Li Y et al (2022) Rates of response to atogepant for migraine prophylaxis among adults: a secondary analysis of a randomized clinical trial. JAMA Netw Open 5:e2215499","journal-title":"JAMA Netw Open"},{"key":"1783_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/03331024211042385","volume":"42","author":"TJ Schwedt","year":"2022","unstructured":"Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H et al (2022) Time course of efficacy of atogepant for the preventive treatment of migraine: results from the randomized, double-blind ADVANCE trial. Cephalalgia 42:3\u201311","journal-title":"Cephalalgia"},{"key":"1783_CR29","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1212\/WNL.0000000000010019","volume":"95","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F et al (2020) One-year sustained efficacy of erenumab in episodic migraine: results of the STRIVE study. Neurology 95:e469\u2013e479","journal-title":"Neurology"},{"key":"1783_CR30","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.clinthera.2020.11.007","volume":"42","author":"TR Smith","year":"2020","unstructured":"Smith TR, Janelidze M, Chakhava G, Cady R, Hirman J, Allan B et al (2020) Eptinezumab for the prevention of episodic migraine: sustained effect through 1 year of treatment in the PROMISE-1 study. Clin Ther 42:2254\u20132265e2253","journal-title":"Clin Ther"},{"key":"1783_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s10194-020-01186-3","volume":"21","author":"S Silberstein","year":"2020","unstructured":"Silberstein S, Diamond M, Hindiyeh NA, Biondi DM, Cady R, Hirman J et al (2020) Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain 21:120","journal-title":"J Headache Pain"},{"key":"1783_CR32","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1136\/jnnp-2018-320242","volume":"90","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Dodick DW, Martinez JM, Ferguson MB, Oakes TM, Zhang Q et al (2019) Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. J Neurol Neurosurg Psychiatry 90:939\u2013944","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"suppl 1","key":"1783_CR33","first-page":"168","volume":"63","author":"R Lipton","year":"2023","unstructured":"Lipton R, Chalermpalanupap N, Nahas-Geiger S, Pozo-Rosich P, McAllister P, Tatsuoka Y et al (2023) Sustained and subsequent response to atogepant among individuals with chronic migraine: post hoc analysis of the PROGRESS trial [abstract P-180]. Headache 63(suppl 1):168\u2013169","journal-title":"Headache"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01783-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01783-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01783-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T07:05:27Z","timestamp":1716275127000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01783-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1783"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01783-6","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"28 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ADVANCE and LTS trials were approved by an institutional review board or independent ethics committee and registered at ClinicalTrials.gov: NCT03777059 (ADVANCE) and NCT03700320 (LTS trial). For each trial, participants provided written informed consent. All study conduct was in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RBL has received research support from the National Headache Foundation, the National Institutes of Health, and the US Food and Drug Administration. He serves as consultant for, advisory board member of, or has received honoraria or research support from AbbVie\/Allergan, Amgen, Biohaven, Dr. Reddy\u2019s Laboratories (Promius), electroCore, Eli Lilly, GlaxoSmithKline, Lundbeck, Merck, Novartis, Teva, Vector, and Vedanta Research. He receives royalties from <i>Wolff\u2019s Headache<\/i>, 8th edition (Oxford University Press, 2009), and Informa. He holds stock\/options in Biohaven and Manistee. SJN has served as consultant for AbbVie, Eli Lilly, Lundbeck, Pfizer, Theranica, and Tonix. She has received honoraria for work in education or publishing from American Academy of Neurology, American Headache Society, Diamond Headache Clinic Research and Educational Foundation, MedLink Neurology, MJH Life Sciences, NACCME, Springer, WebMD\/Medscape, and Wolters Kluwer. PP-R has received, in the last 3 years, personal fees for advisory boards and speaker panels from AbbVie, Amgen, Chiesi, Eli Lilly, Lundbeck, Medscape, Novartis, Pfizer, and Teva, and for serving on the scientific advisory board of Lilly Foundation Spain and Gadea Science Foundation. She is the principal investigator for clinical trials sponsored by AbbVie, Amgen, Biohaven, Eli Lilly, Lundbeck, Novartis, and Teva. Her group has received grants from AbbVie, Era-Net Neuron, European Commission, Instituto Carlos III, International Headache Society, MINECO, Novartis, FEDER RIS3CAT, and Teva. She serves as an associate editor for <i>Cephalalgia<\/i>, <i>Headache<\/i>, <i>Neurologia<\/i>, <i>The Journal of Headache and Pain<\/i>, and <i>Revista de Neurologia<\/i>. She is the Honorary Secretary of the International Headache Society. She does not hold any stock or options. TB has participated in advisory boards for AbbVie, Biohaven, and Theranica. She is a clinical trial investigator for Lundbeck. PM has received research funding from AbbVie, Amgen, Biogen, Biohaven, EMD Serono, Lundbeck, Novartis, and Teva, and has received personal compensation for advisory boards and\/or speakers bureaus for AbbVie, Aeon, Amgen, Biohaven, Lilly, Lundbeck, Revance, and Teva. MF was an employee of AbbVie at the time of study conduct and may hold AbbVie stock. DWD reports the following conflicts: Consulting: Amgen, Atria, CapiThera Ltd., Cerecin, Ceruvia Lifesciences LLC, CoolTech, Ctrl M, Allergan, AbbVie, Biohaven, Escient, GlaxoSmithKline, Halion, Lundbeck, Eli Lilly, Novartis, Impel, Satsuma, Theranica, WL Gore, Genentech, Nocira, Perfood, Praxis, AYYA Biosciences, Revance, Pfizer. Honoraria: American Academy of Neurology, Headache Cooperative of the Pacific, Headache Cooperative of New England, Canadian Headache Society, MF Med Ed Research, Biopharm Communications, CEA Group Holding Company (Clinical Education Alliance LLC), Teva (speaking), Amgen Japan (speaking), Eli Lilly Canada (speaking), Lundbeck (speaking), Pfizer (speaking), Vector Psychometric Group, Clinical Care Solutions, CME Outfitters, Curry Rockefeller Group, DeepBench, Global Access Meetings, KLJ Associates, Academy for Continued Healthcare Learning, Majallin LLC, Medlogix Communications, Medica Communications LLC, MJH Lifesciences, Miller Medical Communications, WebMD Health\/Medscape, Wolters Kluwer, Oxford University Press, Cambridge University Press. Non-profit board membership: American Brain Foundation, American Migraine Foundation, ONE Neurology, Precon Health Foundation, Global Patient Advocacy Coalition, Atria Health Collaborative, Atria Academy of Science and Medicine, Arizona Brain Injury Alliance, Domestic Violence HOPE Foundation\/Panfila, CSF Leak Foundation. Research support: Department of Defense, National Institutes of Health, Henry Jackson Foundation, Sperling Foundation, American Migraine Foundation, Patient-Centered Outcomes Research Institute (PCORI). Stock options\/shareholder\/patents\/board of directors: Ctrl M (options), Aural Analytics (options), Axon Therapeutics (board\/options), ExSano (options), Palion (options), Keimon Medical (options), Man and Science, Healint (options), Theranica (options), Second Opinion\/Mobile Health (options), Epien (options), Nocira (options), Matterhorn (shares), Ontologics (shares), King-Devick Technologies (options\/board), Precon Health (options\/board), ScotiaLyfe (board), EigenLyfe (options\/board), AYYA Biosciences (options), Axon Therapeutics (options\/board), Cephalgia Group (options\/board), Atria Health (options\/employee). Patent 17189376.1-1466:vTitle: Onabotulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis (non-royalty bearing). Patent application submitted: Synaquell\u00ae (Precon Health). YL, NC, and BD are employees of AbbVie and may hold AbbVie stock.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols, clinical study reports, or analysis plans), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent, scientific research, and will be provided following review and approval of a research proposal, Statistical Analysis Plan (SAP), and execution of a Data Sharing Agreement (DSA). Data requests can be submitted at any time after approval in the US and Europe and after acceptance of this manuscript for publication. The data will be accessible for 12 months, with possible extensions considered. For more information on the process or to submit a request, visit the following link:  then select \u201cHome.\u201d","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}}],"article-number":"83"}}